These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 28039080

  • 1. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
    Laberko A, Bogoyavlenskaya A, Shelikhova L, Shekhovtsova Z, Balashov D, Voronin K, Kurnikova E, Boyakova E, Raykina E, Brilliantova V, Pirumova V, Novichkova G, Maschan A, Maschan M.
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Mar; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
    Ding Y, Ru Y, Song T, Guo L, Zhang X, Zhu J, Li C, Jin Z, Huang H, Tu Y, Xu M, Xu Y, Chen J, Wu D.
    Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
    [Abstract] [Full Text] [Related]

  • 4. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
    Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q.
    J Hematol Oncol; 2012 Aug 02; 5():46. PubMed ID: 22856463
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A.
    Pediatr Int; 2017 Sep 02; 59(9):973-978. PubMed ID: 28581032
    [Abstract] [Full Text] [Related]

  • 10. CD3+TCRαβ/CD19+-Depleted Mismatched Family or Unrelated Donor Salvage Stem Cell Transplantation for Graft Dysfunction in Inborn Errors of Immunity.
    Ramanathan S, Lum SH, Nademi Z, Carruthers K, Watson H, Flood T, Owens S, Williams E, Hambleton S, Gennery AR, Slatter M.
    Transplant Cell Ther; 2023 Aug 02; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
    Schachtner T, Reinke P.
    Transpl Infect Dis; 2016 Dec 02; 18(6):881-888. PubMed ID: 27632022
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
    Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, Sosna J, Bhatia M, Kung AL, George D, Garvin JH, Satwani P.
    Biol Blood Marrow Transplant; 2016 Sep 02; 22(9):1646-1653. PubMed ID: 27252110
    [Abstract] [Full Text] [Related]

  • 18. Effect of early EBV and/or CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation.
    Indolfi G, Heaton N, Smith M, Mieli-Vergani G, Zuckerman M.
    Clin Transplant; 2012 Sep 02; 26(1):E55-61. PubMed ID: 21981027
    [Abstract] [Full Text] [Related]

  • 19. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec 02; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 20. Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation.
    Kong X, Xu Z, Wu Y, Tang X, Xue S, Miao M, Han Y, Wang Y, Chen S, Sun A, Qiu H, Wu D, Zhao Y, Chen F.
    J Hematol Oncol; 2024 Oct 12; 17(1):94. PubMed ID: 39396017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.